[1] 安仁芳,苏晓灵. 房颤相关基因在不同人群中的研究进展[J]. 临床医学进展,2022,12(2):1439-1445. [2] Murtaza G, Yarlagadda B, Akella K, et al.Role of the Left Atrial Appendage in Systemic Homeostasis, Arrhythmogenesis, and Beyond[J]. Card Electrophysiol Clin, 2020, 12(1): 21-28. [3] Luigi Di Biase, Andrea NA, Jorge RO.Thrombogenic and Arrhythmogenic Roles of the Left Atrial Appendage in Atrial Fibrillation[J]. Circulation, 2018, 138(18): 2036-2050. [4] Payam SA, Abdi RA.Thromboembolism in Atrial Fibrillation: Role of the Left Atrial Appendage[J]. Card Electrophysiol Clin, 2020, 12(1): 13-20. [5] Belenkov YN, Popova LV, Ilgisonis SI.Management of patients with atrial fibrillation and minor bleeding during therapy with direct oral anti-coagulants[J]. Kardiologiia, 2021, 61(12): 72-81. [6] 马长生. 2019年心房颤动治疗新进展[J]. 临床心血管病杂志,2019,35(11):967-971. [7] Rosati F, de Maat GE, Valente MA, et al. Surgical clip closure of the left atrial appendage[J]. J Cardiovasc Electrophysiol, 2021, 32(10): 2865-2872. [8] 黄从新,张澍,黄德嘉,等. 左心耳干预预防心房颤动患者血栓栓塞事件:目前的认识和建议(2019)[J]. 中华心律失常学杂志,2019,23(5):372-392. [9] Sharma E, Apostolidou E, Sheikh W, et al.Hemodynamic effects of left atrial appendage occlusion[J]. J Interv Card Electrophysiol, 2021: 1-9. [10] Fang R, Wang Z, Zhao X, et al.Stroke risk evaluation for patients with atrial fibrillation: Insights from left atrial appendage with fluid-structure interaction analysis[J]. Computers in Biology and Medicine, 2022, 148: 105897. [11] Tiver KD, Quah J, Lahiri A, et al.Atrial fibrillation burden: An update-the need for a CHA2DS2-VASc-AFBurden score[J]. Europace, 2021, 23(5): 665-673. [12] Tarantini AG, Gd A, Bs B, et al.The Impact of CHA2DS2 -VASc and HAS-BLED Scores on Clinical Outcomes in the Amplatzer Amulet Study[J]. JACC: Cardiovascular Interventions, 2020, 13(18): 2099-2108. [13] Holmes DR Jr, Alkhouli M.Treatment Effects of Left Atrial Appendage Occlusion[J]. JACC: Cardiovascular Interventions, 2020, 13(18): 2109-2111. [14] Safavi-Naeini PA, Rasekh AB.Where We Stand on Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation[J]. Texas Heart Institute journal, 2016, 43(4): 320-323. [15] Richard LA, Monica MU, Alan GO, et al.Interleukin-6 Is a Risk Factor for Atrial Fibrillation in Chronic Kidney Disease: Findings from the CRIC Study[J]. PLoS ONE, 2017, 11(2): e0148189. [16] Stanciu AE, Vatasescu RG, Stanciu MM, et al.The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation[J]. Cytokine, 2018, 103: 63. [17] Pawluk H, Woźniak A, Grześk G, et al.The Role of Selected Pro-Inflammatory Cytokines in Pathogenesis of Ischemic Stroke[J]. Clin Interv Aging, 2020, 15: 469-484. |